An excerpt of EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease in 2024

Wenjing NI; Nan GENG; Xue BAI; Jie LI

doi:10.12449/JCH240810

Volume 40 Issue 8

Aug. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(8): 1567-1574

PDF( 1636 KB)

An excerpt of EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease in 2024

DOI: 10.12449/JCH240810

Wenjing NI^{1, 2},
Nan GENG²,
Xue BAI²,
Jie LI^{1, 2
,
,
,}

1.
Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine，Nanjing 210008，China
2.
Department of Infectious Diseases，Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School，Nanjing 210008，China

More Information

Corresponding author: LI Jie， lijier@nju.edu.cn （ORCID： 0000-0003-0973-8645）
Received Date: 2024-06-24
Accepted Date: 2024-07-07
Published Date: 2024-08-25

Abstract

Abstract

In June 2024， the European Association for the Study of the Liver， the European Association for the Study of Diabetes， and the European Association for the Study of Obesity jointly released the latest edition of clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease （MASLD）， which comprehensively elaborates on the definition， prevalence rate， natural disease history， screening， diagnosis， and treatment of MASLD and proposes 33 statements and 72 recommendations. This article gives an excerpt of the key points in this document.
- Fatty Liver,
- Europe,
- Practice Guideline

FullText(HTML)

References(1)

References

[1]

European Association for the Study of the Liver(EASL), European Association for the Study of Diabetes(EASD), European Association for the Study of Obesity(EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease(MASLD)[J]. Obes Facts, 2024. DOI: 10.1159/000539371.[ Online ahead of print]

Relative Articles

[1]	Yanbin NI, Jiye ZHU. An excerpt of EASL clinical practice guidelines on liver transplantation （2024 edition）[J]. Journal of Clinical Hepatology, 2025, 41(2): 240-246. doi: 10.12449/JCH250208
[2]	Manman XU, Nan GENG, Yu CHEN. An excerpt of EASL clinical practice guidelines on acute－on－chronic liver failure （2023）[J]. Journal of Clinical Hepatology, 2023, 39(10): 2321-2327. doi: 10.3969/j.issn.1001-5256.2023.10.008
[3]	Huimin LIU, Wenting CHEN, Shilian LI, Hongmei GONG, Qing. MAO. Key points of EASL Clinical Practice Guidelines on hepatitis delta virus （2023）[J]. Journal of Clinical Hepatology, 2023, 39(11): 2558-2563. doi: 10.3969/j.issn.1001-5256.2023.11.007
[4]	Dandan JIA, Guiying ZHU, Shiyao LIAO, Hui ZHANG, Hui GUO, Lili YANG, Changmiao WANG. Interpretation of European Society for Clinical Nutrition and Metabolism practical guideline : Clinical nutrition in liver disease (2020)[J]. Journal of Clinical Hepatology, 2021, 37(7): 1553-1557. doi: 10.3969/j.issn.1001-5256.2021.07.015
[5]	YANG Jia, RAO HuiYing. EASL recommendations on treatment of hepatitis C: Final update of the series (2020)[J]. Journal of Clinical Hepatology, 2020, 36(12): 2681-2687. doi: 10.3969/j.issn.1001-5256.2020.12.009
[6]	Yu LeCheng, Lai RongTao, Chen ChengWei. Key points and interpretation of EASL clinical practice guidelines: Drug-induced liver injury (2019)[J]. Journal of Clinical Hepatology, 2019, 35(6): 1242-1250. doi: 10.3969/j.issn.1001-5256.2019.06.013
[7]	Zhou YiXia, Gao Ya, Li Wu. An excerpt of EASL Clinical Practice Guidelines on nutrition in chronic liver disease (2018)[J]. Journal of Clinical Hepatology, 2018, 34(11): 2305-2310. doi: 10.3969/j.issn.1001-5256.2018.11.008
[8]	Yang Jia, Rao HuiYing, Wei Lai. Introduction and interpretation of EASL recommendations on treatment of hepatitis C 2018[J]. Journal of Clinical Hepatology, 2018, 34(8): 1622-1631. doi: 10.3969/j.issn.1001-5256.2018.08.007
[9]	Song Yang, Zhou Fei, Chen LiGang. An excerpt of EASL clinical practice guidelines: Management of alcohol-related liver disease (2018)[J]. Journal of Clinical Hepatology, 2018, 34(7): 1415-1419. doi: 10.3969/j.issn.1001-5256.2018.07.010
[10]	Ge NingLing, Xue TongChun, Ye ShengLong. Interpretation of EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma (2018)[J]. Journal of Clinical Hepatology, 2018, 34(6): 1187-1190. doi: 10.3969/j.issn.1001-5256.2018.06.011
[11]	Yu JiongJie, Yan WenTao, Quan Bing, Yang Tian. Recommendations for EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma (2018)[J]. Journal of Clinical Hepatology, 2018, 34(6): 1183-1186. doi: 10.3969/j.issn.1001-5256.2018.06.010
[12]	Li Yan, Tang ShanHong. An excerpt of EASL clinical practice guidelines on hepatitis E virus infection 2018[J]. Journal of Clinical Hepatology, 2018, 34(7): 1410-1414. doi: 10.3969/j.issn.1001-5256.2018.07.009
[13]	Yang Min, Zhang ShengGuo, Lu MingQin. EASL clinical practical guidelines on the management of acute(fulminant) liver failure(2017)[J]. Journal of Clinical Hepatology, 2017, 33(10): 1883-1887. doi: 10.3969/j.issn.1001-5256.2017.10.007
[14]	Yu LeCheng, Hou JinLin. The highlights of EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2017, 33(6): 1017-1032. doi: 10.3969/j.issn.1001-5256.2017.06.002
[15]	Huang Cheng, Sun HuiChuan. EASL clinical practice guidelines on the management of benign liver tumors (2016)[J]. Journal of Clinical Hepatology, 2016, 32(8): 1439-1445. doi: 10.3969/j.issn.1001-5256.2016.08.001
[16]	Shi YingHong, Tian MengXin, Fan Jia. Recommendations for EASL clinical practice guidelines: liver transplantation（2015）[J]. Journal of Clinical Hepatology, 2016, 32(3): 429-431. doi: 10.3969/j.issn.1001-5256.2016.03.005
[17]	Gao Fan, Hu FengRong, Qi XingShun. An excerpt of 2015 EASL clinical practical guidelines: vascular diseases of the liver [J]. Journal of Clinical Hepatology, 2016, 32(1): 40-43. doi: 10.3969/j.issn.1001-5256.2016.01.005
[18]	Shen ShanShan, Dai MingJia, Yan XueBing. Interpretation and analysis of EASL recommendations on treatment of hepatitis C 2016[J]. Journal of Clinical Hepatology, 2016, 32(12): 2258-2262. doi: 10.3969/j.issn.1001-5256.2016.12.006
[20]	Chang BinXia, Li BaoSen, Zou ZhengSheng. An excerpt of EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease(2016)[J]. Journal of Clinical Hepatology, 2016, 32(8): 1450-1454. doi: 10.3969/j.issn.1001-5256.2016.08.003

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 蓝婧，陈丽芬，江秋维，程读创，韦月辽. 肥胖人群肝脂肪变性相关因素及与IGN代谢指标的关系. 吉林医学. 2025(03): 527-529 .
Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (944) PDF downloads(269)

An excerpt of EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease in 2024

DOI: 10.12449/JCH240810

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

An excerpt of EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease in 2024

DOI: 10.12449/JCH240810

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content